Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.650
-0.110 (-6.25%)
At close: Nov 17, 2026, 4:00 PM EST
1.640
-0.010 (-0.61%)
After-hours: Nov 17, 2026, 4:18 PM EST

Company Description

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers.

Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression.

The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Silexion Therapeutics Corp
Silexion Therapeutics logo
CountryIsrael
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees14
CEOIlan Hadar

Contact Details

Address:
12 Abba Hillel Road
Ramat Gan, 5250606
Israel
Phone972 3 756 4999
Websitesilexion.com

Stock Details

Ticker SymbolSLXN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code2022416
CUSIP NumberG1281K148
ISIN NumberKYG1281K1638
SIC Code2836

Key Executives

NamePosition
Ilan Hadar M.B.A.Chairman and Chief Executive Officer
Mirit Horenshtein HadarExecutive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D.Chief Scientific and Development Officer

Latest SEC Filings

DateTypeTitle
Nov 16, 20268-KCurrent Report
Nov 12, 202610-QQuarterly Report
Nov 12, 20268-KCurrent Report
Nov 9, 2026EFFECTNotice of Effectiveness
Nov 9, 20268-KCurrent Report
Oct 28, 2026S-3Registration statement under Securities Act of 1933
Oct 26, 20268-KCurrent Report
Oct 19, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 5, 2026DEF 14AOther definitive proxy statements
Sep 30, 20268-KCurrent Report